Design Therapeutics, Inc. Common Stock
DSGNStock
$12.61+244.46%52W
Market Cap$787.58M
P/E—
Div yield—
Beta1.61
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)27.52%
Price vs S&P 500 (4W)25.52%
VGM Score69.89
Market Capitalization$787.58M
Earnings Surprise History
Q1 26-0.29est. -0.33
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.09
4.33
4.33
4.31
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
DSGNDesign Therapeutics, Inc. Common Stock | — | — | B | $12.61 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Design Therapeutics is a clinical-stage biopharmaceutical company developing GeneTAC molecules, a proprietary platform of small-molecule therapeutics designed to treat inherited diseases caused by nucleotide repeat expansions such as Friedreich Ataxia, Myotonic Dystrophy, Huntington's Disease, and Fuchs Endothelial Corneal Dystrophy. The company's GeneTAC candidates are designed to address the underlying genetic causes of these conditions, offering potential disease-modifying treatments for currently incurable genetic disorders.